EGFR and non-small cell lung carcinoma: In a recent phase 2 trial (NCT01869166), patients with advanced NSCLC with an over 50% EGFR expression received the anti-EFGR CAR T cell treatment, and the patients were able to tolerate the therapy without severe toxicity for 3–5 days at a time [124].